Gilead Sciences (GILD) closed the latest trading day at $87.23, indicating a -1.05% change from the previous session's end. This move lagged the S&P 500's daily loss of 0.92%. Meanwhile, the Dow ...

On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $88.16 which represents a slight increase of $1.87 or 2.17% from the prior close of $86.29. The stock opened at ...

Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...

Signaturefd LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 12.1% in the third ...

The withdrawal of the FDA accelerated approval for locally advanced or metastatic urothelial carcinoma, a type of bladder ...

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

Biotech firm Gilead Sciences has announced plans to voluntarily withdraw the US accelerated approval for Trodelvy ...

US drugmakers Gilead Sciences (Nasdaq: GILD) and Merck & Co (NYSE: MRK) have announced new results from a Phase II clinical ...

Bengaluru: Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients ...

Middlebury College Earth and Climate Sciences students experience the excitement of the geological and environmental sciences in interesting, dynamic, and fun settings in the Green Mountains and ...